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Oestrogen-regulated genes in breast cancer:
association of pLIVI with response to endocrine
therapy
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Summary Northern hybridization analyses of the oestrogen-inducible mRNAs pLIV1 and pS2 were compared with oestrogen receptor (ER)
immunocytochemistry assessments in 40 untreated primary or early recurrent breast tumours. Significant associations were observed
between pLIVl/ER (P < 0.03), pS2/ER (P < 0.001) and pLIV1/pS2 (P < 0.04) status. After disease recurrence, patients were treated with
assessable courses of endocrine therapies. Positive pLIV1, pS2 and ER statuses in primary disease were consequentlyfound to be predictive
of endocrine responsiveness in the secondary lesions (P < 0.03, P < 0.02, P < 0.005 respectively). However, despite these associations, a
number of pLIV1i- and/or pS2-positive tumours failed to respond to therapy.
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The selection of breast cancer patients for endocrine therapy is
most frequently made on the basis of tumour oestrogen-receptor
(ER) protein content. However, the predictive capability of ER
status alone is not absolute (Nicholson et al, 1991). While few ER-
negative patients respond to such therapies, perhaps half of ER-
positive patients will also gain no clinically defined benefit.
It has been postulated that coassessment of ER and oestrogen-
inducible genes or protein products, as markers of functioning
ER-mediated cellular growth mechanisms, might give better
predictive results. As such, the additional measurements oftumour
PR and pS2 protein content have been shown to partly improve
selectivity (Horwitz and McGuire, 1977; Foekens et al, 1990).
Our study evaluates the significance of expression of the
oestrogen-inducible pLIVl (Manning et al, 1988) and pS2
mRNAs in primary breast cancer as alternative predictors of
endocrine responsiveness in recurrent breast cancer in comparison
with ER protein.
MATERIALS AND METHODS
Patients
Tumour samples were obtained from 40 patients with histologi-
cally proven, previously untreated primary or recurrent breast
cancer presenting to the breast clinics ofProfessor R Blamey, City
Hospital, Nottingham, during the period May 1987-October 1993.
Fourteen were premenopausal (mean age 44 years) and 26 post
menopausal (mean age 67 years). Details of tumour grade were
available on 38 patients, of whom three were reported as grade 1,
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13 as grade 2 and 22 as grade 3. Twenty-seven tumours were
described as infiltrating ductal (no special type), five
mixed/tubular, two mixed ductal/lobular and the remainder as
single cases of lobular, medullary, atypical medullary, mixed
ductal/mucinous and ductal carcinoma in situ.
Endocrine therapy
All patients were given systemic endocrine therapy as initial treat-
ment after either locally advanced or locoregional recurrences
of their disease. Responses to these treatments were assessed
according to UICC (Hayward et al, 1977) and British Breast Group
criteria (1974). Most premenopausal patients received the LH-RH
agonist goserelin (3.6 mg depot every 28 days) alone (n = 5) or in
combination with tamoxifen (20 mg twice daily, n = 7). Two
premenopausal patients and 22 post-menopausal patients received
tamoxifen alone, while four post-menopausal patients were given
the progestogen megestrol acetate (160 mg twice daily).
Responses to first-line endocrine therapy were recorded in 13 out
of 40 (32.5%) cases (complete response in four cases, partial
response in nine). Disease stabilization was achieved in 13 (32.5%)
patients while 14 (35%) patients' disease progressed despite treat-
ment. Responses to tamoxifen were recorded in 11 of 24 (45.8%)
cases and in two ofseven (28.6%) combination tamoxifen/goserelin-
treated patients. No responses to goserelin alone or to megestrol
acetate were recorded, although two offive patients and one offour
patients did achieve disease stabilization respectively.
RNA extraction and Northern analysis
Tumour material was rapidly frozen upon excision and stored at
-70°C before analysis. Portions of tissue were divided for
immunocytochemistry and RNA extraction. Procedures for RNA
extraction, using aguanidiniumthiocyanate lysis/caesium chloride
density centrifugation method, electrophoresis and Northern
blotting were as detailed by Manning et al (1988, 1993).
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Table 1 Associations between pLIV1 and pS2 mRNA and ERICA protein
status
(A)
p-LIV1 positive p-LIV1 negative Total P-value
ERICA positive 13 (32.5) 15 (37.5) 28 (70) 0.030
ERICA negative 1 (2.5) 11 (27.5) 12 (30)
Total 14 (35) 26 (65) 40 (100)
(B)
pS2 positive pS2 negative Total P-value
ERICA positive 16 (40) 12 (30) 28 (70) 0.001
ERICA negative 0 (0) 12 (30) 12 (30)
Total 16 (40) 24 (60) 40 (100)
(C)
p-LIV1 positive p-LIV1 negative Total P-value
pS2 positive 9 (22.5) 7 (17.5) 16 (40) 0.041
pS2 negative 5 (12.5) 19 (47.5) 24 (60)
Total 14 (35) 26 (65) 40 (100)
Table 2 Associations between marker status and response to endocrine
therapy
(A)
p-LIV1 positive p-LIV1 negative Total P-value
Responders 8 (20) 5 (12.5) 13 (32.5) 0.031
Static and PDs 6 (15) 21 (52.5) 27 (67.5)
Total 14 (35) 26 (65) 40 (100)
(B)
pS2 positive pS2 negative Total P-value
Responders 9 (22.5) 4 (10) 13 (32.5) 0.015
Static and PDs 7 (17.5) 20 (50) 27 (67.5)
Total 16 (40) 24 (60) 40 (100)
(C)
ERICA positive ERICA negative Total P-value
Responders 13 (32.5) 0 (0) 13 (32.5) 0.004
Static and PDs 15 (37.5) 12 (30) 27 (67.5)
Total 28 (70) 12 (30) 40 (100)
Template pLIVI and pS2 cDNA were labelled by a
random-hexamer oligonucleotide procedure using [32P]dCTP
(300 Ci mmol-', Amersham).
Filters bearing 10 ig oftotal RNA per lane were prehybridized
as previously described (Manning et al, 1988, 1993). Activity-
matched aliquots of labelled probe were then added to the
prehybridization mixture and hybridization performed for 17 h.
Filters were washed with increasing stringency, air dried and
autoradiography performed.
Autoradiographs were assessed by video densitometry (BioRad,
UK) and levels of expression normalized against internal controls
and the constant expression gene GAPDH. Cut-off values for
pLIV1 and pS2 mRNA positivity, accounting for background
hybridization and basal expression in oestrogen-deprived cells,
were as previously established (Manning et al, 1993) (i.e. densito-
metry score of. 1.0 for pLIVI and . 0.1 for pS2).
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Figure 1 Correlation analyses of pLIV1 and pS2 mRNA and ER protein
Immunocytochemistry
The immunocytochemical assay procedures for ER protein evalu-
ation, using the ERICA monoclonal kit (Abbott Diagnostics, UK)
on frozen sections, have been described previously (Walker et al,
1988). Assays were performed on sections adjacent to the excised
tumour used for RNA extraction. Internal control sections and
negative control antisera were included. Assessment of specific
immunocytochemical staining of tumour cells was performed on
at least ten fields per section and the H-score calculated as previ-
ously described (McClelland et al, 1991). Previous studies show
that a cut-off for ERICA positivity of > 0.02 has significance as a
predictor of the endocrine responsiveness of recurrent breast
cancer, and this value is used here (Nicholson et al, 1991).
Statistics
Subgroup analyses were performed using Fisher's exact test for
2 x 2 contingency tables for small data groups. Associations
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within these small subgroups are reported as two-sided P-values.
Comparative analysis of levels of mRNA and protein expression
were assessed by calculation ofthe non-parametric Spearman rank
correlation coefficient.
RESULTS
Two predominant mRNA species of 4.4 kb and 2.3 kb were
hybridized by 32P-labelled pLIV1 cDNA in these samples. pS2
cDNA recognized a single smaller mRNA species of 0.6 kb.
Fourteen of 40 (35%) specimens expressed significant levels of
pLIVl mRNA while pS2 mRNA was found in 16 (40%) cases.
Twenty-eight (70%) tumours were ERICA positive. Significant
associations between pLIV1 mRNA and ER protein status
(P < 0.03) (Table IA), between pS2 mRNA and ER protein status
(P < 0.001) (Table 1B) and between the expression of pLIV1 and
pS2 (P = 0.04) (Table IC) were observed. The linearity of these
associations was tested by Spearman's rank correlation coefficient
analysis and revealed weakly significant trends towards linearity
throughout [pLIV1/ERICA r = 0.365, P = 0.022 (Figure IA);
pLIVl/pS2 r = 0.372, P = 0.018 (Figure 1B); pS2/ERICA r =
0.376, P = 0.018 (Figure IC)].
After disease recurrence, patients were treated with various
forms of endocrine therapy and the subsequent response of their
disease to these was compared with the potential marker status of
their primary tumours. Thus, analysis of primary cancer pLIV1
mRNA status and objective response to first-line endocrine
therapy revealed a significant association (P = 0.031) (Table 2A),
with 8 of 13 (61.5%) responders being initially pLIV1 positive.
Significantly, 21 of 27 (77.8%) patients whose disease failed to
respond to first-line endocrine therapy were initially pLIV1 nega-
tive. Combining static disease patients with responders in this
analysis reduced the predictive capabilities ofpLIVi status below
significance.
Similarly, 9 of 13 (69.2%) responding patients expressed signifi-
cant levels ofpS2 mRNA in theirprimary tumours (P = 0.015) (Table
2B). As with pLIVl, most patients [20 out of 27 (74.1%)] relapsing
with endocrine treatment-unresponsive disease were initially pS2
negative. Addition of the static disease group to the responders
negated the predictive capability ofpS2 mRNA expression.
ERICA status was very significantly associated with response
(P < 0.004), with all 13 (100%) responders expressing ER protein
in their original sample (Table 2C). Conversely, 12 of 27 (44.4%)
patients suffering progressive disease were ER negative. The
predictive capacity of ERICA was not quite maintained after the
inclusion ofstatic disease patients with the responders (P = 0.071).
DISCUSSION
We report that the expression of either pLIV1 or pS2 mRNAs in a
small group of untreated primary or early recurrent breast cancer
patients is significantly associated with the outcome of first-line
endocrine therapy on initial or further recurrent disease. However,
the presumed association between the oestrogen-regulated expres-
sion of pLIVi and pS2 mRNAs and a response to anti-oestrogen
therapy proved far from absolute. Thus, while most responders to
therapy were indeed pLIV1 positive and non-responders pLIV1
negative, a significant proportion [11 of 40 (27.5%)] were either
pLIV1 positive but non-responding or more significantly pLIV1-
negative responders. Similar results were observed for pS2 mRNA
expression. In contrast, while approximately half of ER-positive
patients did not respond to therapy, all who did were ER positive
or, in other words, no ER-negative patients responded to therapy.
A number of possible explanations may be offered to account
for the lack of concordance between endocrine response and
oestrogen-inducible gene expression. Transcription of such genes
is normally mediated through binding of the ER-ligand complex
to specific regulatory sequences, the oestrogen response elements
(reviewed by Parker, 1993). However, other classes of steroid
hormone response elements and growth factor response elements
frequently occur upstream of these genes, implying great
complexity in their transcriptional regulation. The pLIV1 gene has
thus been shown to be inducible not only by oestradiol but also by
progesterone, 5a-dihydroxy-testosterone, epidermal growth factor
and by cAMP-elevatory compounds (El-Tanani and Green, 1995,
1996, 1997).
It is further recognized that even the oestrogen-responsive cell
experiences considerable mitogenic influence from growth factors
via their specific receptors, the resultant signal transduction
cascades and subsequent gene activation. Oestrogens are often
intimately involved in these sequences of events. The growth
factor-activated transcription factor c-fos, for example, is tran-
siently inducible by oestradiol (Weitz and Bresciani, 1993) and
may have down-regulatory effects on ER functioning by
heterodimerizing with the receptor complex, while c-jun may
inhibit ER-DNA binding to ERE (Doucas et al, 1991). It follows
that mechanisms that promote growth factor/AP- 1 signalling path-
ways (Angel and Karin, 1991) could lead to the loss ofreliance on
E,-ER-mediated pathways (Gee et al, 1996). Alternatively, lack of
concordance between oestrogen-inducible gene expression and
endocrine response may relate to expression of mutated ER
protein. Up to 30% of breast cancers express subpopulations of
mutant ERs in association with wild type (Fuqua et al, 1991). Of
these mutants, half appear incapable of binding to DNA, others
cannot complex with ligand (Foster et al, 1991). Significant
numbers ofeither ofthese groups could, by reducing the ability of
a cell to maintain levels ofcontrolled ER-regulated gene transcrip-
tion, lead to the promotion of growth factor-mediated pathways
and a loss ofoestrogen sensitivity. Based on the above, the current
strategy of using oestrogen-regulated gene products as markers of
hormone responsiveness may be substantially flawed. Indeed,
given the complex mechanisms resulting in controlled cellular
growth and development and the heterogeneous nature of tumour
cell populations, it seems unlikely that any single marker analysis
will ever prove infallible in detecting the endocrine-sensitive
phenotype. While this is as undoubtedly true for pLIV1 as for any
other oestrogen-regulated gene, its additional potential as a marker
of lymph node involvement (Manning et al, 1994) holds promise
and is under investigation in our laboratories.
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